86 related articles for article (PubMed ID: 21717885)
1. Effect of radiation therapy to immunological and virological status in HIV/AIDS-cancer patients, preliminary report.
Siraprapasiri P; Tharavichitkul E; Suntornpong N; Tovanabutra C; Anekthananon T; Meennuch E; Tangshevinsirikul T
J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S88-93. PubMed ID: 21717885
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
3. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
4. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
6. [Detection of the viral load and its use as a virological marker in the follow-up of HIV-1-positive patients].
Hodara VL; Monticelli A; Benetucci J; Lasala M; Jauregui Rueda H; Libonatti O; García Messina O; Reboredo G; Bogdanowicz E; Bases O; Pampuro S; Salomón H
Rev Argent Microbiol; 1998; 30(1):1-7. PubMed ID: 9629601
[TBL] [Abstract][Full Text] [Related]
7. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
8. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
10. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
Moore DM; Hogg RS; Chan K; Tyndall M; Yip B; Montaner JS
AIDS; 2006 Feb; 20(3):371-7. PubMed ID: 16439870
[TBL] [Abstract][Full Text] [Related]
11. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Helicobacter pylori can facilitate immune reconstitution in HIV-1-infected immunological non-responders.
Magen E; Elbirt D; Agmon-Levin N; Mishal J; Sthoeger Z
Int J Infect Dis; 2010 Apr; 14(4):e322-7. PubMed ID: 19699671
[TBL] [Abstract][Full Text] [Related]
14. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
15. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
[No Abstract] [Full Text] [Related]
16. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.
Guihot A; Tubiana R; Breton G; Marcelin AG; Samri A; Assoumou L; Goncalves E; Bricaire F; Costagliola D; Calvez V; Rouzioux C; Autran B; Katlama C; Carcelain G; ;
AIDS; 2010 Feb; 24(4):614-7. PubMed ID: 19952710
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population.
Reiche EM; Bonametti AM; Morimoto HK; Morimoto AA; Wiechemann SL; Matsuo T; Vissoci Reiche F; Vogler IH
Int J Mol Med; 2008 Mar; 21(3):387-95. PubMed ID: 18288387
[TBL] [Abstract][Full Text] [Related]
18. Characterization of GBV-C infection in HIV-1 infected patients.
Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
[TBL] [Abstract][Full Text] [Related]
19. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
